From crisis to opportunity: A perspective on the heparin crisis

• References

• 1 Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008; 141: 757-763.
• 2 Baxter provides update on investigation. Baxter Investigation. Update (14 March 2008). http://www.baxter.com/products/biopharmaceuticals/downloads/heparin_03–14–08.pdf
• 3 Communication. Information on heparin sodium injection. US Food and Drug Administration. http://www.fda.gov/cder/drug/infopage/heparin/default.htm
• 4 Guerrini M, Becatti D, Shriver Z. et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-675.
• 5 Hojima Y, Cochrane CG, Wiggins RC. et al. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984; 63: 1453-1459.
• 6 Kishimoto TK, Viswanathan K, Ganguly T. al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-2467.
• 7 Schwartz LB. Heparin Comes Clean. N Engl J Med 2008; 358: 2505-2509.
• 8 Blossom DB, Kallen Aj, Patel PR. et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359: 2674-2684.
• 9 Greinacher A, Warkentin TE. Contaminated heparin. N Engl J Med 2008; 359: 1291-1292.
• 10 Wang L, Buchanan S, Meyerhoff ME. Detection of high-charge density polyanion contaminants in biomedical heparin preparations using potentiometric polyanion sensors. Anal Chem. 2008 epub.
• 11 Spencer JA, Kauffman JF, Reepmeyer JC. et al. Screening of heparin API by near infrared reflectance and Raman spectroscopy. J Pharm Sci. 2008 epub.
• 12 Trehy ML, Reepmeyer JC, Kolinski RE. et al. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal. 2008 epub.
• 13 Tami C, Puig M, Reepmeyer JC. et al. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials 2008; 29: 4808-4814.
• 14 Alban S, Lühn S. Prothrombin time for detection of contaminated heparins. N Engl J Med 2008; 359: 2732-2734.
• 15 Zhang Z, Weïwer M, Li B. et al. Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem 2008; 51: 5498-5501.
• 16 Laurencin CT, Nair L. The FDA and safety – Beyond the heparin crisis. Nat Biotechnol 2008; 26: 621-623.
• 17 Avorn J. Coagulation and adulteration – Building on science and policy lessons from 1905. N Engl J Med 2008; 358: 2429-2431.
• 18 Leiden JM. Canaries and coalmines, and the drug supply. Nat Biotechnol 2008; 26: 624-626.
• 19 Guerrini M, Raman R, Venkataraman G. et al. A novel computational approach to integrate NMR spectroscopy and capillary electrophoresis for structure assignment of heparin and heparan sulfate oligosaccharides. Glycobiology 2002; 12: 713-719.
• 20 Conrad HE. Heparin Binding Proteins. 1998. Academic Press; San Diego, CA, USA.: